Report Detail

Pharma & Healthcare Global Acute Vulvovaginal Candidiasis Treatment Market Size, Status and Forecast 2021-2027

  • RnM4284408
  • |
  • 04 February, 2021
  • |
  • Global
  • |
  • 97 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Clotrimazole
    • 1.2.3 Nystatin
    • 1.2.4 Fluconazole
    • 1.2.5 Ketoconazole
    • 1.2.6 Terbinafine
    • 1.2.7 Terconazole
    • 1.2.8 Others
  • 1.3 Market by Application
    • 1.3.1 Global Acute Vulvovaginal Candidiasis Treatment Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Hospital Pharmacies
    • 1.3.3 Retail Pharmacies
    • 1.3.4 Online Pharmacies
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Perspective (2016-2027)
  • 2.2 Acute Vulvovaginal Candidiasis Treatment Growth Trends by Regions
    • 2.2.1 Acute Vulvovaginal Candidiasis Treatment Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Acute Vulvovaginal Candidiasis Treatment Historic Market Share by Regions (2016-2021)
    • 2.2.3 Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Regions (2022-2027)
  • 2.3 Acute Vulvovaginal Candidiasis Treatment Industry Dynamic
    • 2.3.1 Acute Vulvovaginal Candidiasis Treatment Market Trends
    • 2.3.2 Acute Vulvovaginal Candidiasis Treatment Market Drivers
    • 2.3.3 Acute Vulvovaginal Candidiasis Treatment Market Challenges
    • 2.3.4 Acute Vulvovaginal Candidiasis Treatment Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Acute Vulvovaginal Candidiasis Treatment Players by Revenue
    • 3.1.1 Global Top Acute Vulvovaginal Candidiasis Treatment Players by Revenue (2016-2021)
    • 3.1.2 Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Players (2016-2021)
  • 3.2 Global Acute Vulvovaginal Candidiasis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Acute Vulvovaginal Candidiasis Treatment Revenue
  • 3.4 Global Acute Vulvovaginal Candidiasis Treatment Market Concentration Ratio
    • 3.4.1 Global Acute Vulvovaginal Candidiasis Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Acute Vulvovaginal Candidiasis Treatment Revenue in 2020
  • 3.5 Acute Vulvovaginal Candidiasis Treatment Key Players Head office and Area Served
  • 3.6 Key Players Acute Vulvovaginal Candidiasis Treatment Product Solution and Service
  • 3.7 Date of Enter into Acute Vulvovaginal Candidiasis Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Acute Vulvovaginal Candidiasis Treatment Breakdown Data by Type

  • 4.1 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Type (2016-2021)
  • 4.2 Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Type (2022-2027)

5 Acute Vulvovaginal Candidiasis Treatment Breakdown Data by Application

  • 5.1 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Application (2016-2021)
  • 5.2 Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size (2016-2027)
  • 6.2 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Type
    • 6.2.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2021)
    • 6.2.2 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2022-2027)
    • 6.2.3 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2027)
  • 6.3 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Application
    • 6.3.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2021)
    • 6.3.2 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2022-2027)
    • 6.3.3 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2027)
  • 6.4 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country
    • 6.4.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2016-2021)
    • 6.4.2 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.3 Canada

7 Europe

  • 7.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size (2016-2027)
  • 7.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Type
    • 7.2.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2021)
    • 7.2.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2022-2027)
    • 7.2.3 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2027)
  • 7.3 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Application
    • 7.3.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2021)
    • 7.3.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2022-2027)
    • 7.3.3 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2027)
  • 7.4 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country
    • 7.4.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2016-2021)
    • 7.4.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size (2016-2027)
  • 8.2 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Type
    • 8.2.1 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Application
    • 8.3.1 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region
    • 8.4.1 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size (2016-2027)
  • 9.2 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Type
    • 9.2.1 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2021)
    • 9.2.2 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2022-2027)
    • 9.2.3 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2027)
  • 9.3 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Application
    • 9.3.1 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2021)
    • 9.3.2 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2022-2027)
    • 9.3.3 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2027)
  • 9.4 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country
    • 9.4.1 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2016-2021)
    • 9.4.2 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size (2016-2027)
  • 10.2 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Type
    • 10.2.1 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Application
    • 10.3.1 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country
    • 10.4.1 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Mycovia Pharmaceuticals, Inc
    • 11.1.1 Mycovia Pharmaceuticals, Inc Company Details
    • 11.1.2 Mycovia Pharmaceuticals, Inc Business Overview
    • 11.1.3 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Introduction
    • 11.1.4 Mycovia Pharmaceuticals, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
    • 11.1.5 Mycovia Pharmaceuticals, Inc Recent Development
  • 11.2 Scynexis, Inc
    • 11.2.1 Scynexis, Inc Company Details
    • 11.2.2 Scynexis, Inc Business Overview
    • 11.2.3 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Introduction
    • 11.2.4 Scynexis, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
    • 11.2.5 Scynexis, Inc Recent Development
  • 11.3 Basilea Pharmaceutica Ltd
    • 11.3.1 Basilea Pharmaceutica Ltd Company Details
    • 11.3.2 Basilea Pharmaceutica Ltd Business Overview
    • 11.3.3 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Introduction
    • 11.3.4 Basilea Pharmaceutica Ltd Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
    • 11.3.5 Basilea Pharmaceutica Ltd Recent Development
  • 11.4 Astellas Pharma Inc
    • 11.4.1 Astellas Pharma Inc Company Details
    • 11.4.2 Astellas Pharma Inc Business Overview
    • 11.4.3 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Introduction
    • 11.4.4 Astellas Pharma Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
    • 11.4.5 Astellas Pharma Inc Recent Development
  • 11.5 Grupo Ferrer Internacional, S.A
    • 11.5.1 Grupo Ferrer Internacional, S.A Company Details
    • 11.5.2 Grupo Ferrer Internacional, S.A Business Overview
    • 11.5.3 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Introduction
    • 11.5.4 Grupo Ferrer Internacional, S.A Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
    • 11.5.5 Grupo Ferrer Internacional, S.A Recent Development
  • 11.6 Pacgen Life Science Corporation
    • 11.6.1 Pacgen Life Science Corporation Company Details
    • 11.6.2 Pacgen Life Science Corporation Business Overview
    • 11.6.3 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Introduction
    • 11.6.4 Pacgen Life Science Corporation Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
    • 11.6.5 Pacgen Life Science Corporation Recent Development
  • 11.7 NovaDigm Therapeutics, Inc
    • 11.7.1 NovaDigm Therapeutics, Inc Company Details
    • 11.7.2 NovaDigm Therapeutics, Inc Business Overview
    • 11.7.3 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Introduction
    • 11.7.4 NovaDigm Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
    • 11.7.5 NovaDigm Therapeutics, Inc Recent Development
  • 11.8 Cidara Therapeutics, Inc
    • 11.8.1 Cidara Therapeutics, Inc Company Details
    • 11.8.2 Cidara Therapeutics, Inc Business Overview
    • 11.8.3 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Introduction
    • 11.8.4 Cidara Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
    • 11.8.5 Cidara Therapeutics, Inc Recent Development
  • 11.9 Amplyx Pharmaceuticals Inc
    • 11.9.1 Amplyx Pharmaceuticals Inc Company Details
    • 11.9.2 Amplyx Pharmaceuticals Inc Business Overview
    • 11.9.3 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Introduction
    • 11.9.4 Amplyx Pharmaceuticals Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
    • 11.9.5 Amplyx Pharmaceuticals Inc Recent Development
  • 11.10 Pfizer, Inc.
    • 11.10.1 Pfizer, Inc. Company Details
    • 11.10.2 Pfizer, Inc. Business Overview
    • 11.10.3 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Introduction
    • 11.10.4 Pfizer, Inc. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
    • 11.10.5 Pfizer, Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Acute Vulvovaginal Candidiasis Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Acute Vulvovaginal Candidiasis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

    Segment by Type
    Clotrimazole
    Nystatin
    Fluconazole
    Ketoconazole
    Terbinafine
    Terconazole
    Others

    Segment by Application
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia
    Latin America
    Mexico
    Brazil
    Rest of Latin America
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of MEA

    By Company
    Mycovia Pharmaceuticals, Inc
    Scynexis, Inc
    Basilea Pharmaceutica Ltd
    Astellas Pharma Inc
    Grupo Ferrer Internacional, S.A
    Pacgen Life Science Corporation
    NovaDigm Therapeutics, Inc
    Cidara Therapeutics, Inc
    Amplyx Pharmaceuticals Inc
    Astellas Pharma Inc


    Summary:
    Get latest Market Research Reports on Acute Vulvovaginal Candidiasis Treatment. Industry analysis & Market Report on Acute Vulvovaginal Candidiasis Treatment is a syndicated market report, published as Global Acute Vulvovaginal Candidiasis Treatment Market Size, Status and Forecast 2021-2027. It is complete Research Study and Industry Analysis of Acute Vulvovaginal Candidiasis Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,900.00
    $5,850.00
    $7,800.00
    2,812.37
    4,218.55
    5,624.74
    3,258.88
    4,888.32
    6,517.76
    421,999.50
    632,999.25
    843,999.00
    284,836.50
    427,254.75
    569,673.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report